ATE321452T1 - Tetracycline verbindungen zur behandlung von spezifischen krebsarten - Google Patents

Tetracycline verbindungen zur behandlung von spezifischen krebsarten

Info

Publication number: ATE321452T1
Authority: AT; Austria
Prior art keywords: cancer; cells; growth; tetracycline compounds; treatment
Prior art date: 1997-01-15

Application number

AT98902437T

Other languages

English (en)

Inventor

Lorne M Golub

Thomas F Mcnamara

Nungavaram S Ramamurthy

Hsi-Ming Lee

Sanford Simon

Balakrishna L Lokeshwar

Marie G Selzer

Normal L Block

Original Assignee

Univ New York State Res Found

Univ Miami

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-15

Filing date

1998-01-15

Publication date

2006-04-15

1998-01-15 Application filed by Univ New York State Res Found, Univ Miami filed Critical Univ New York State Res Found

2006-04-15 Application granted granted Critical

2006-04-15 Publication of ATE321452T1 publication Critical patent/ATE321452T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 4
-1 TETRACYCLINE COMPOUNDS Chemical class 0.000 title abstract 2
239000004098 Tetracycline Substances 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
229960002180 tetracycline Drugs 0.000 title abstract 2
229930101283 tetracycline Natural products 0.000 title abstract 2
235000019364 tetracycline Nutrition 0.000 title abstract 2
206010027476 Metastases Diseases 0.000 abstract 2
230000005907 cancer growth Effects 0.000 abstract 2
230000002401 inhibitory effect Effects 0.000 abstract 2
230000009401 metastasis Effects 0.000 abstract 2
NBRQRXRBIHVLGI-OWXODZSWSA-N (4as,5ar,12ar)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C(C2=O)[C@@H]1C[C@@H]1[C@@]2(O)C(O)=C(C(=O)N)C(=O)C1 NBRQRXRBIHVLGI-OWXODZSWSA-N 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
206010009944 Colon cancer Diseases 0.000 abstract 1
206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
230000000844 anti-bacterial effect Effects 0.000 abstract 1
230000004663 cell proliferation Effects 0.000 abstract 1
208000029742 colonic neoplasm Diseases 0.000 abstract 1
230000003013 cytotoxicity Effects 0.000 abstract 1
231100000135 cytotoxicity Toxicity 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
201000005202 lung cancer Diseases 0.000 abstract 1
208000020816 lung neoplasm Diseases 0.000 abstract 1
201000001441 melanoma Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT98902437T 1997-01-15 1998-01-15 Tetracycline verbindungen zur behandlung von spezifischen krebsarten ATE321452T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/783,655 US5837696A (en)	1997-01-15	1997-01-15	Method of inhibiting cancer growth

Publications (1)

Publication Number	Publication Date
ATE321452T1 true ATE321452T1 (de)	2006-04-15

Family

ID=25130005

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98902437T ATE321452T1 (de)	1997-01-15	1998-01-15	Tetracycline verbindungen zur behandlung von spezifischen krebsarten

Country Status (11)

Country	Link
US (2)	US5837696A (de)
EP (1)	EP0971585B1 (de)
JP (1)	JP4428727B2 (de)
KR (1)	KR20000070212A (de)
AT (1)	ATE321452T1 (de)
AU (1)	AU729886B2 (de)
CA (1)	CA2277865C (de)
DE (1)	DE69834024T2 (de)
ES (1)	ES2262221T3 (de)
PT (1)	PT971585E (de)
WO (1)	WO1998031224A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6429204B1 (en)	1997-01-15	2002-08-06	University Of Miami	Method of inhibiting cancer growth
US5837696A (en) *	1997-01-15	1998-11-17	The Research Foundation Of State University Of New York	Method of inhibiting cancer growth
AU2001599A (en) *	1997-12-19	1999-07-05	New York University	Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha
US6277061B1 (en)	1998-03-31	2001-08-21	The Research Foundation Of State University Of New York	Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) *	1998-09-11	2000-01-18	The Research Foundation Of State University Of New York	Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) *	1998-09-21	1999-11-02	The Research Foundation Of State University Of New York	Method of preventing acute lung injury
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CA2356929A1 (en) *	1998-12-23	2000-07-06	G.D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia
US6984619B1 (en) *	1999-03-19	2006-01-10	Arch Development Corporation	Method for protection against tumor metastasis formation
DE10032256C2 (de) *	2000-07-03	2003-06-05	Infineon Technologies Ag	Chip-ID-Register-Anordnung
EP1383483A4 (de) *	2001-04-05	2006-08-09	Collagenex Pharm Inc	Kontrollierte freisetzung von tetracyclin-verbindungen und tetracyclin-derivativen
EP2332547A1 (de)	2001-07-13	2011-06-15	Paratek Pharmaceuticals, Inc.	Tetracyclinverbindungen zur Behandlung von entzündlicher Darmerkrankung
US20060194773A1 (en) *	2001-07-13	2006-08-31	Paratek Pharmaceuticals, Inc.	Tetracyline compounds having target therapeutic activities
AU2002341970B2 (en) *	2001-10-05	2008-02-14	Tetragenex Pharmaceuticals, Inc.	Tetracycline derivatives and methods of use thereof
PE20030701A1 (es) *	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
EP2311798A1 (de)	2002-01-08	2011-04-20	Paratek Pharmaceuticals, Inc.	4-Dedimethylamin-Tetracyclinverbindungen
WO2003075857A2 (en)	2002-03-08	2003-09-18	Paratek Pharmaceuticals, Inc.	Amino-methyl substituted tetracycline compounds
CA2479877C (en)	2002-03-21	2012-08-21	Paratek Pharmaceuticals, Inc.	Substituted tetracycline compounds
CA2500134A1 (en) *	2002-05-06	2003-11-13	Collagenex Pharmaceuticals, Inc.	Methods of simultaneously treating mucositis and fungal infection
AU2003245295B2 (en) *	2002-05-20	2008-01-03	Collagenex Pharmaceuticals, Inc.	Methods of treating allergic reactions
AU2003261161B2 (en)	2002-07-12	2009-09-10	Paratek Pharmaceuticals, Inc	3, 10, and 12a substituted tetracycline compounds
EP1562608A4 (de) *	2002-10-24	2010-09-01	Paratek Pharm Innc	Verfahren zur verwendung von substituiertentetracyclin-verbindungen zur modulierung der rna
CA2521885C (en)	2003-04-07	2013-06-25	Shire Laboratories, Inc.	Once daily formulations of tetracyclines
WO2005009943A2 (en)	2003-07-09	2005-02-03	Paratek Pharmaceuticals, Inc.	Substituted tetracycline compounds
EP1656341A1 (de)	2003-07-09	2006-05-17	Paratek Pharmaceuticals, Inc.	Prodrugs von 9-aminomethyltetracyclinverbindungen
EP2332904A3 (de)	2004-01-15	2012-04-11	Paratek Pharmaceuticals, Inc.	Derivate von Tetracyclin-Verbindungen
EP2301916A3 (de)	2004-10-25	2011-09-28	Paratek Pharmaceuticals, Inc.	4-Aminotetracycline und Verfahren zu ihrer Verwendung
EP2269978A3 (de)	2004-10-25	2011-09-21	Paratek Pharmaceuticals, Inc.	Substituierte Tetracyclinverbindungen
US20070093455A1 (en) *	2005-07-21	2007-04-26	Paul Abato	10-substituted tetracyclines and methods of use thereof
IL270446B2 (en)	2006-12-21	2023-10-01	Paratek Pharm Innc	A tetracycline compound, a pharmaceutical preparation containing the tetracycline compound, and the tetracycline compound or the pharmaceutical preparation for the treatment of the tetracycline-responsive condition
EP2120963B1 (de)	2006-12-21	2018-09-12	Paratek Pharmaceuticals, Inc.	Substituierte tetracyclinverbindungen zur behandlung von entzündlichen hautstörungen
EP2213655A1 (de)	2007-04-27	2010-08-04	Paratek Pharmaceuticals, Inc.	Verfahren zur Reinigung von Aminoalkyl-Tetracyclinverbindungen
EA201070233A1 (ru) *	2007-07-06	2010-08-30	Паратек Фармасьютикалс, Инк.	Способы синтеза замещённых соединений тетрациклина (варианты)
TW202332671A (zh) *	2008-05-19	2023-08-16	美商ＰｒｔｋＳｐｖ２公司	四環素化合物之甲苯磺酸鹽及同素異形體
CN105367440A (zh)	2008-08-08	2016-03-02	四相制药公司	C7-氟取代的四环素化合物
CN102459153A (zh)	2009-05-08	2012-05-16	四相制药公司	四环素类化合物
HUE037852T2 (hu)	2009-08-28	2018-09-28	Tetraphase Pharmaceuticals Inc	Tetraciklin-vegyületek
WO2011109899A1 (en) *	2010-03-10	2011-09-15	University Health Network	Use of tigecycline for treatment of cancer
PL2552890T3 (pl)	2010-03-31	2017-07-31	Tetraphase Pharmaceuticals, Inc.	Policykliczne związki tetracyklinowe
EA031523B1 (ru)	2012-08-31	2019-01-31	Тетрафейз Фармасьютикалс, Инк.	Тетрациклиновые соединения
JP6513576B2 (ja) *	2013-01-14	2019-05-15	ヘルスクリニックスリミテッド	抗がん剤および使用
HRP20240605T1 (hr)	2016-10-19	2024-07-19	Tetraphase Pharmaceuticals, Inc.	Kristalni oblici eravaciklina
US11229657B2 (en)	2017-04-21	2022-01-25	Lunella Biotech, Inc.	Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy
EP3612187B1 (de)	2017-04-21	2022-04-13	Lunella Biotech, Inc.	Vitamin c und doxycyclin: eine synthetische letale kombinationstherapie zur eradikation von krebsstammzellen (cscs)
CU20190092A7 (es)	2017-05-19	2020-10-20	Lunella Biotech Inc	Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
CA3063450A1 (en)	2017-05-19	2018-11-22	Lunella Biotech, Inc.	Companion diagnostics for mitochondrial inhibitors
US12570604B2 (en)	2018-11-09	2026-03-10	Tetraphase Pharmaceuticals, Inc.	Polymorphic forms of a tetracycline compound and uses thereof
CN115006411A (zh) *	2022-07-26	2022-09-06	中南大学湘雅医院	依拉环素类化合物的应用、药物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5308839A (en) *	1989-12-04	1994-05-03	The Research Foundation Of State University Of New York	Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
JP3016587B2 (ja) *	1989-12-04	2000-03-06	ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク	非ステロイド抗炎症剤及びテトラサイクリンの配合
US5668122A (en) *	1993-07-28	1997-09-16	Fife; Rose S.	Method to treat cancer with tetracyclines
US5567693A (en) *	1994-12-13	1996-10-22	American Cyanamid Company	Method for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5563130A (en) *	1994-12-13	1996-10-08	American Cyanamid Company	Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5574026A (en) *	1994-12-13	1996-11-12	American Cyanamid Company	Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5837696A (en) *	1997-01-15	1998-11-17	The Research Foundation Of State University Of New York	Method of inhibiting cancer growth

1997
- 1997-01-15 US US08/783,655 patent/US5837696A/en not_active Expired - Lifetime
1998
- 1998-01-15 US US09/007,645 patent/US6100248A/en not_active Expired - Lifetime
- 1998-01-15 WO PCT/US1998/000332 patent/WO1998031224A1/en not_active Ceased
- 1998-01-15 AU AU59104/98A patent/AU729886B2/en not_active Ceased
- 1998-01-15 ES ES98902437T patent/ES2262221T3/es not_active Expired - Lifetime
- 1998-01-15 JP JP53443498A patent/JP4428727B2/ja not_active Expired - Fee Related
- 1998-01-15 CA CA002277865A patent/CA2277865C/en not_active Expired - Fee Related
- 1998-01-15 KR KR1019997006438A patent/KR20000070212A/ko not_active Ceased
- 1998-01-15 DE DE69834024T patent/DE69834024T2/de not_active Expired - Lifetime
- 1998-01-15 PT PT98902437T patent/PT971585E/pt unknown
- 1998-01-15 AT AT98902437T patent/ATE321452T1/de active
- 1998-01-15 EP EP98902437A patent/EP0971585B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
KR20000070212A (ko)	2000-11-25
US5837696A (en)	1998-11-17
PT971585E (pt)	2006-08-31
AU5910498A (en)	1998-08-07
DE69834024T2 (de)	2006-12-07
EP0971585A4 (de)	2001-01-24
US6100248A (en)	2000-08-08
EP0971585A1 (de)	2000-01-19
ES2262221T3 (es)	2006-11-16
JP4428727B2 (ja)	2010-03-10
CA2277865A1 (en)	1998-07-23
CA2277865C (en)	2009-06-02
JP2001508794A (ja)	2001-07-03
EP0971585B1 (de)	2006-03-29
AU729886B2 (en)	2001-02-15
DE69834024D1 (de)	2006-05-18
WO1998031224A1 (en)	1998-07-23

Legal Events

Date

Code

Title

Description

2007-01-15

UEP

Publication of translation of european patent specification

Ref document number: 0971585

Country of ref document: EP

Publication	Publication Date	Title
DE69834024D1 (de)	2006-05-18	Tetracycline verbindungen zur behandlung von spezifischen krebsarten
DE69830072D1 (de)	2005-06-09	Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE368466T1 (de)	2007-08-15	Androgensyntheseinhibitoren
MX9804009A (es)	1998-11-29	Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.
DK1214292T3 (da)	2007-10-15	Tyrosinderivater
DE60040981D1 (de)	2009-01-15	BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
DE60015070D1 (de)	2004-11-25	Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
ZA988826B (en)	1999-03-29	Acylsulfamoylbenzamides crop protection compositions comprising them and processes for their preparation
ATE355079T1 (de)	2006-03-15	Behandlung von prostata-krebs mit anti-erbb2 antikörpern
ATE208210T1 (de)	2001-11-15	Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
EP0709090A3 (de)	1996-08-28	Zusammensetzungen zur Behandlung von resistenten Tumoren
DE602004015811D1 (de)	2008-09-25	Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
HUP0104688A2 (hu)	2002-03-28	Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
DE60021381D1 (de)	2005-08-25	Chinonverbindungen zur behandlung von krankheiten
BR9912327A (pt)	2001-05-02	Inibidores da uroquinase
BR0008788A (pt)	2001-11-06	Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase
DE69902523D1 (de)	2002-09-19	Verwendung von erythropoietin zur behandlung von multiple myelom
ATE190352T1 (de)	2000-03-15	Dorsalgewebe beeinflussender faktor und zusammensetzungen
DE69921130D1 (de)	2004-11-18	Verfahren und stoffe zur behandlung des prostatakarzinomes
MXPA03002495A (es)	2004-05-05	Proceso para preparacion de compuestos de n-(fenil sustituido)-3-alquil, aril- y heteroarilsulfonil-2-hidroxi-2-alquil- y haloalquilpropanamida.
ATE196083T1 (de)	2000-09-15	Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE60229414D1 (de)	2008-11-27	Verwendung von aplidine in der behandlung von pankreaskrebs
DE60137721D1 (de)	2009-04-02	Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
IL189502A0 (en)	2008-06-05	Methods and compositions for inhibiting neoplastic cell growth
DE69715668D1 (de)	2002-10-24	N-(pyridinylamino)isoindoline und verwandte verbindungen